3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
8
Other hematologic neoplasm
6
Tumor-Agnostic
4
Thoracic
3
Other solid neoplasm
3
Lymphoid
3
Genitourinary
3
Gastrointestinal
3
Myeloid
2
Head & Neck
2
Gynecologic
2
Dermatologic
2
Plasma cell
1
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
fludarabine phosphate
140
Cyclophosphamide
132
Busulfan
102
Peripheral Blood Stem Cell Transplantation
95
Imatinib Mesylate
94
Mycophenolic Acid
91
Cytarabine
82
Azacitidine
80
Tacrolimus
79
Cyclosporine
78
Whole-Body Irradiation
77
fludarabine
74
Antilymphocyte Serum
71
Methotrexate
65
Filgrastim
63
nilotinib
59
Melphalan
51
Decitabine
49
Radiotherapy
43
Dasatinib
34
Granulocyte Colony-Stimulating Factor
33
ruxolitinib
31
Clofarabine
31
Etoposide
30
thymoglobulin
29
Thiotepa
29
Cord Blood Stem Cell Transplantation
28
sargramostim
27
Methylprednisolone
26
Stem Cell Transplantation
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Tablets
×
Myeloid
×
Clear all
NCT02852486
2025-03-30
EDI-PIO
University of Campinas, Brazil
Phase 2
Completed
31 enrolled
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled